Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus
Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus have?
Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus has 10 citations in the OpenAlex counts ScholarIQ stores.
When was Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus published?
Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus has 2023 year in the ScholarIQ index.
What is the open-access status of Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus?
Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus has closed oa status in the ScholarIQ index.
What is the DOI of Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus?
The DOI for Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus is on the source record.
What is the PMID of Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus?
The PMID for Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus is on the source record.
What is the OpenAlex record for Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus?
The OpenAlex for Safety, efficacy and pharmacokinetics of low‐dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus is on the source record.